Endocrine Abstracts

Background: Subspecialty tumor boards (TB) are uncommon and their benefit has not been clearly demonstrated for patients and providers alike. We tried to determine the decision patterns of a newly minted neuroendocrine neoplasm (NEN) tumor board (TB) and the factors behind those.Methods: We retrospectively reviewed all NEN TB recommendations from 07/2018 to 12/2021 and recorded patient characteristics, TB outcomes and associations between them.<p cla...